Trexquant Investment LP Has $7.93 Million Stake in Genmab A/S (NASDAQ:GMAB)

Trexquant Investment LP boosted its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 495.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 379,936 shares of the company's stock after purchasing an additional 316,089 shares during the period. Trexquant Investment LP owned about 0.06% of Genmab A/S worth $7,929,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Brandywine Global Investment Management LLC acquired a new stake in Genmab A/S in the fourth quarter valued at about $33,804,000. JPMorgan Chase & Co. boosted its stake in shares of Genmab A/S by 3,049.3% in the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock valued at $8,507,000 after purchasing an additional 394,670 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after purchasing an additional 280,900 shares in the last quarter. ABC Arbitrage SA bought a new stake in shares of Genmab A/S during the 4th quarter valued at approximately $3,692,000. Finally, AIMZ Investment Advisors LLC bought a new position in Genmab A/S in the 4th quarter valued at approximately $3,525,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Stock Up 4.7 %

GMAB traded up $0.85 during trading on Wednesday, reaching $18.83. 2,025,002 shares of the stock traded hands, compared to its average volume of 1,007,530. The stock's 50-day moving average is $20.51 and its 200 day moving average is $21.38. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $30.41. The stock has a market capitalization of $12.46 billion, a PE ratio of 10.82, a P/E/G ratio of 2.65 and a beta of 1.07.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, equities research analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Finally, Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.